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 Abstract 
 Aim/Goal: To recommend a set of neuropsychological and physical exercise tests for research-
ers to assess cognition and physical fitness in clinical trials with older patients with dementia; 
to create consensus, decrease heterogeneity, and improve research quality.  Methods: A litera-
ture search (2005–2011) yielded 89 randomized controlled trials. To provide information on test 
recommendations the frequency of test use, effect size of the test outcome, study quality, and 
psychometric properties of tests were analyzed.  Results: Fifty-nine neuropsychological tests 
(cognitive domains: global cognition, executive functioning, memory, and attention) and 10 
exercise tests (physical domains: endurance capacity, muscle strength, balance, and mobility) 
were found.  Conclusion:  The Severe Impairment Battery, Mini Mental State Examination, and 
Alzheimer Disease Assessment Scale – cognitive subscale were recommended to measure glob-
al cognition. The Verbal Fluency Test Category/Letters, Clock Drawing Test, and Trail Making 
Test-B were recommended to measure executive functioning. No specific memory test could 
be recommended. The Digit Span Forward, Digit Span Backward, and Trail Making Test-A were 
recommended to measure attention. As physical exercise tests, the Timed Up and Go and Six 
Meter Walk for mobility, the Six Minute Walk Distance for endurance capacity, and the Tinetti 
Balance Scale were recommended.  Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
 With the worldwide trend of an aging population, the number of patients with dementia 
will increase dramatically in the coming decades  [1] . Dementia is characterized by a loss of 
neurons and atrophy of brain tissue  [2–5] . Eventually, this leads to limitations in cognitive 
performance of executive functioning, memory, and attention  [6, 7] . The neurodegenerative 
processes in the brain go hand in hand with limitations in physical performance of endur-
ance capacity, muscle strength, balance, and mobility  [6, 8] . Eventually, decline in cognitive 
performance and physical performance results in problems in activities of daily living and 
behavior, leading to institutionalization and a decreased quality of life  [3, 9, 10] . Therefore, 
prevention of decline and preferably an improvement in both cognitive and physical perfor-
mance in patients with dementia are of utmost importance.
 With the growing impact of dementia on today’s society, new treatments need to be de-
veloped that effectively reduce the limitations caused by a decline of cognitive and physical 
performance in patients with dementia  [11] . Meta-analysis and systematic reviews reported 
that pharmacological (e.g. medication) and non-pharmacological (e.g. exercise) interven-
tions may have a positive effect on cognition and physical functioning  [12–18] . However, the 
individual studies in these reviews showed ambiguous results and the tests that measured 
cognitive and physical functioning appeared to show large heterogeneity. Consequently, the 
comparability of the outcomes of clinical trials is hampered  [19] . Therefore, future interven-
tion studies that aim to improve cognitive functioning, physical functioning, or a combina-
tion of both should strive to use a limited number of generally accepted, feasible, reliable, and 
valid tests that adequately cover the domains of cognitive and physical functioning in pa-
tients with dementia. This study is intended to contribute to this goal.
 Recommendations on cognitive assessment tests for the purpose of diagnosing dementia 
were recently provided by Chaves et al.  [20] and Young et al.  [21] . Information regarding the 
tests on cognition that researchers should use for measuring treatment effects, however, is 
not available yet. To the authors’ knowledge, recommendations regarding the use of exercise 
tests evaluating physical functioning in clinical trials are fully lacking.
 The aim of this systematic review is to give up-to-date recommendations of both neuro-
psychological and physical exercise tests for researchers who have the aim to investigate 
treatment effects on cognition and physical functioning in older patients with dementia. 
Firstly, a comprehensive overview of tests on the basis of randomized controlled trials (RCTs) 
is presented. Frequently used neuropsychological and physical exercise tests are evaluated in 
relation with study quality of RCTs, nature of the interventions in RCTs, type of dementia 
that was studied, and sensitivity to change of the tests. Secondly, the reliability and validity 
of frequently used tests was reviewed. 
 Methods 
 Data Sources 
 Between August 2010 and August 2011, computer databases PubMed, EMBASE, Bio-
logical abstracts, Web of Science (ISI), PsycINFO, CINAHL, and Cochrane Library were 
searched for relevant studies published between 2005 and 2011. Limits for the searches in 
the computer databases were set on: clinical trial, humans, and age  6 65 years. Keywords 
in the search included terms from Medical Subject Headings (MESH) and EMBASE the-
saurus (EMTREE). The following terms were used in the MESH database and EMTREE 
thesaurus: dementia, Alzheimer disease, vascular dementia, frontotemporal dementia, 
Lewy body disease, neuropsychological tests, and exercise tests. Keywords for dementia 
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(dementia OR Alzheimer disease OR vascular dementia OR frontotemporal dementia OR 
Lewy body disease) were combined (with ‘AND’) with terms that expressed the use of neu-
ropsychological or exercise tests (neuropsychological tests OR exercise tests). In addition, 
reference lists of reviews regarding the subject were thoroughly hand searched for addi-
tional studies.
 Inclusion Criteria 
 Studies were included if they met the following criteria: (1) the design was a RCT; (2) the 
participants had a diagnosis of dementia; (3) the participants were on average older than 65 
years; (4) neuropsychological tests and/or exercise tests were used to measure the effects of 
an intervention, and (5) the study was written in English, German, French or Dutch.
 Selection Process 
 After the literature search, a first selection of studies was made according to their titles, 
followed by a selection after reading the abstracts. Two reviewers (WB and MvH) indepen-
dently performed both steps to identify those studies that met the inclusion criteria (agree-
ment 94%, disagreement 6%). Disagreement was solved with full-text screening. Full-text 
analysis to check the inclusion criteria was performed for the studies identified in the pre-
ceding steps. Subsequently, reviews were hand searched for clinical trials that were not al-
ready found in the literature search. Finally, full-text analysis of and data extraction from the 
selected studies was performed.
 Data Extraction 
 From the selected RCTs the following data were extracted: neuropsychological tests, 
physical exercise tests, type of dementia, sample size, and data regarding the intervention 
description (e.g. pharmacological, exercise). For each neuropsychological or physical exercise 
test the overall means and standard deviations were calculated from all RCTs that used a 
given test. Further, on the basis of the selected RCTs the overall means and standard devia-
tions were calculated for age, baseline scores, and posttest scores. 
 Effect Size 
 In order to express the sensitivity to change for each neuropsychological or physical ex-
ercise test, Cohen’s  d effect sizes (ESs) for a test were calculated on the basis of the selected 
RCTs  [22, 23] . If the mean and standard deviation of pretest and posttest were presented in 
the RCT, the following formula was used:
 d = [(post exp – pre exp ) – (post cont – pre cont )]/ Sqrt [([ s 2 pre exp (n exp ) +  s 2 pre cont (n cont )]/[n exp + n cont ]) + 
([ s 2 post exp (n exp ) +  s 2 post cont (n cont )]/[n exp + n cont ])/2]  [24] 
 If the means and standard deviations were not presented in the RCT, the  F statistic was 
used with the following formula:
 d =  Sqrt [ F ([(n exp + n cont )/(n exp   n cont )]   [(n exp + n cont )/(n exp + n cont – 2)])]  [24] 
 The overall ES was calculated as the mean of individual ESs weighted for the sample size. 
Cohen’s benchmarks were used to indicate small  ( d = 0.20), medium ( d = 0.50), and large
( d = 0.80) ESs  [22] . 
 Study Quality 
 Study quality of each RCT that used a given test was assessed with the Physiotherapy 
Evidence Database (PEDro)  [25] . According to the PEDro scoring system, a score of 9–10 was 
considered as excellent, a score of 6–8 as good, a score of 4–5 as moderate, and a score of 0–3 
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as poor  [25] . For further analysis of neuropsychological and physical exercise tests in this 
review, the study quality of at least 5 RCTs must be good or excellent.
 Reliability and Validity of Frequently Used Tests 
 After identifying the tests that were used in  6 5 good or excellent quality RCTs, a second 
search in PubMed was conducted through September 2011 to select the studies aimed at re-
porting the reliability and validity of these tests as evidenced in a population with dementia. 
Searches were performed by combining the terms ‘reliability’ OR ‘validity’ OR ‘reproducibil-
ity of results’ in combination with (with ‘AND’) keywords for dementia and the selected neu-
ropsychological and physical exercise tests. By means of references, additional reliability and 
validity studies were searched.
 Results 
 Study Characteristics 
 The literature searches for RCTs yielded a total of 840 potentially relevant publications. 
Eventually, 178 publications were full text screened of which 89 were excluded. A flowchart 
of the process is presented in  figure 1 . The results are described in two separate sections: (1) 
neuropsychological tests and (2) exercise tests. These sections describe the test use in RCTs 
(number of RCTs), test use related to intervention type, test use related to dementia type, ESs 
measured with the tests, and study quality of RCTs (PEDro).  Table 1 describes 59 neuropsy-
chological tests that covered the cognitive domains global cognition, executive functioning, 
memory, and attention. Thereafter,  table 2 describes the psychometric data of the neuropsy-
chological tests that were most often used. Finally, 10 exercise tests that covered the physical 
domains endurance capacity, muscle strength, balance, and mobility are presented in  table 3 . 
 Neuropsychological Tests 
 Frequency of Test Use 
 As is shown in  table 1 , global cognitive functioning was measured most often with the 
Mini Mental State Examination (MMSE) (n = 54), Alzheimer’s Disease Assessment Scale – 
cognitive subscale (ADAS-cog) (n = 43), and the Severe Impairment Battery (SIB) (n = 8). 
Tests for global cognitive functioning were used more often in comparison with neuropsy-
chological tests that covered a specific cognitive area.
 Thirty-two domain-specific neuropsychological tests were used in 63 RCTs, of which 7 
tests were used in  6 5 RCTs. Executive functioning was measured with the Verbal Fluency 
Test Category (n = 12), Clock Drawing Test (n = 6), Verbal Fluency Test Letters (n = 6), and 
the Trail Making Test-B (n = 5). Attention was measured with the Digit Span Forward (n = 
8), Digit Span Backward (n = 7), and Trail Making Test-A (n = 6).
 In summary, global cognitive tests were used more often than neuropsychological tests 
that covered a specific cognitive area. Frequently used neuropsychological tests that were 
used in  6 5 RCTs covered the cognitive domains executive functioning and attention. Tests 
that were used in  1 5 RCTs which measured the cognitive domain memory were not found.
 Dementia Type 
 A majority of the participants were diagnosed with Alzheimer’s disease (AD; 84%) or 
vascular dementia (VaD; 7%) ( table 1 ). Neuropsychological tests that were only administered 
in RCTs with AD patients were the SIB (global cognitive functioning), Verbal Fluency Test 
Letters (executive functioning), Trail Making Test-A, Digit Span Forward, and Digit Span 
Backward (attention). Tests used in RCTs with AD or VaD patients were the MMSE and 
593
Dement Geriatr Cogn Disord Extra 2012;2:589–609
 DOI: 10.1159/000345038 
 Published online: December 8, 2012 
E X T R A
 Bossers et al.: Recommended Measures for the Assessment of Cognitive and Physical 
Performance in Older Patients with Dementia: A Systematic Review  
www.karger.com/dee
 © 2012 S. Karger AG, Basel 
ADAS-cog (global cognitive functioning), Verbal Fluency Test Category, Clock Drawing 
Test, and Trail Making Test-B (executive functioning). Tests that were used in RCTs with 
only VaD, Lewy body disease, Pick’s disease, and frontotemporal dementia patients were not 
found.
 Effect Size 
 Pooled ESs ranged from small ( d = –0.16) to large ( d = 1.58). The global cognitive test 
Rapid Evaluation of Cognitive Functioning measured a large ES ( d = 1.12). The global cogni-
tive tests SIB ( d = 0.34), ADAS-cog ( d = 0.19), and MMSE ( d = 0.09) showed small overall ESs. 
Overall ESs were small for both pharmacological and non-pharmacological RCTs. Further-
more, two neuropsychological tests that measured memory revealed large pooled ESs with 
the Visual Reproduction Test ( d = 1.58) and the Syndrome Kurtz Test ( d = 0.82). The Verbal 
Fluency Test Category that measures executive functioning measured a medium pooled ES 
( d = 0.61). 
 Fig. 1. Flow chart of literature 
search and study selection. 
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MMSE (global functioning) 
[26–79]
54 7,606 pharmacological (39), 
cognitive (9), exercise (5), 
acupuncture (1)
75.886.7 58 AD (80), 
VaD (18), 
LB (2)
8.084.0 small E (6), G 
(45), Mo 
(3), P (0)
ADAS-cog (global functioning) 
[26–28, 31, 32, 35, 39, 41, 43, 
47, 48, 51, 54, 55, 58, 61, 63, 64, 
67, 68, 70–72, 75, 77, 80–97]
43 10,133 pharmacological (37), 
cognitive (5), exercise (1)
74.486.7 59 AD (81), 
VaD (17), 
LB (2)
24.4811.0 small E (12), G 
(28), Mo 
(3), P (0)
Verbal Fluency Test Category 
(EF) [31, 36, 46, 47, 56, 98–104]
12 726 pharmacological (5), 
cognitive (2), exercise (1), 
hand move-ment (1),
airway stimuli (1), CES
(1), nerve stimuli (1)
74.287.1 56 AD (47), 
VaD (29), 
n.r. (24)
10.989.2 medium E (4), G 
(6), Mo 
(1), P (1)
SIB (global functioning) 
[30, 37, 66, 73, 74, 105–107]
8 2,134 pharmacological (8) 76.687.7 67 AD (100) 69.3819.2 small E (3), G 
(5), Mo 
(0), P (0)
Digit Span Forward (attention) 
[31, 33, 49, 99, 101–104]
8 342 pharmacological (1), 
cognitive (2), exercise (1), 
hand move-ment (1),
airway stimuli (1), CES
(1), nerve stimuli (1)
82.686.7 55 AD (76),
n.r. (24)
5.482.3 small E (3), G 
(4), Mo 
(0), P (1)
Digit Span Backward (attention) 
[31, 49, 99, 101–104]
7 280 cognitive (2), exercise (1), 
hand movement (1),
airway stimuli (1), CES
(1), nerve stimuli (1)
82.286.5 50 AD (44),
n.r. (56)
3.981.5 small E (3), G 
(3), Mo 
(0), P (1)
Clock Drawing Test (EF) 
[42, 50, 56, 95, 100, 108]
6 1,674 pharmacological (5), 
exercise (1)
72.187.7 68 AD (82), 
VaD (17), 
LB (1)
4.583.2 small E (3), G 
(2), M (0), 
P (1)
Trail Making Test-A 
(attention) 
[31, 42, 83, 101–103]
6 1,502 pharmacological (3), 
cognitive (1), airway
stimuli (1), CES (1)
73.888.0 67 AD (98), 
FTD (2)
161882.5 small E (1), G 
(4), Mo 
(0), P (1)
Verbal Fluency Test Letters 
(EF) [36, 56, 99, 101–103]
6 319 pharmacological (1), 
cognitive (1), exercise (1), 
airway stimuli (1), CES
(1), nerve stimuli (1)
78.985.6 44 AD (56), 
PD (44)
16.384.6 small E (2), G 
(3), Mo 
(0), P (1)
Trail Making Test-B (EF) 
[27, 31, 47, 98, 101]
5 214 pharmacological (3), 
cognitive (1), airway 
stimuli (1)
73.986.2 58 AD (100) 242.8891.3 small E (2), G 
(3), Mo 
(0), P (0)
Logical Memory Test – 
immediate recall (memory) 
[28, 49, 69, 70]
4 277 pharmacological (2), 
cognitive (2)
75.686.8 69 AD (100) 11.584.7 small E (2), G 
(2), Mo 
(0), P (0)
Logical Memory Test – 
delayed recognition (memory) 
[28, 49, 69, 70]
4 277 pharmacological (2), 
cognitive (2)
75.686.8 69 AD (100) 2.882.9 small E (2), G 
(2), Mo 
(0), P (0)
Logical Memory Test – 
delayed recall (memory) 
[28, 49, 69, 70]
4 277 pharmacological (2), 
cognitive (2)
75.686.8 69 AD (100) 0.981.6 small E (2), G 
(2), Mo 
(0), P (0)
Eight Word Test – immediate 
recall (memory) [99, 102–104]
4 196 exercise (1), hand
movement (1), CES (1),
nerve stimuli (1)
84.786.1 62 AD (38), 
n.r. (62)
17.688.1 small E (2), G 
(1), Mo 
(0), P (1)
Eight Word Test – delayed 
recall (memory) [99, 102–104]
4 196 exercise (1), hand
movement (1), CES (1),
nerve stimuli (1)
84.786.1 62 AD (38), 
n.r. (62)
0.3580.94 small E (2), G 
(1), Mo 
(0), P (1)
Eight Word Test – delayed 
recognition (memory) 
[99, 102–104]
4 196 exercise (1), hand
movement (1), CES (1),
nerve stimuli (1)
84.786.1 62 AD (38), 
n.r. (62)
10.783.9 small E (2), G 
(1), Mo 
(0), P (1)
Rivermead Behavioral Memory 
Test – face recognition
(memory) [99, 102–104]
4 196 exercise (1), hand
movement (1), CES (1),
nerve stimuli (1)
84.686.1 59 AD (54), 
n.r. (46)
6.683.5 small E (2), G 
(1), Mo 
(0), P (1)
Rivermead Behavioral Memory 
Test – picture recognition 
(memory) [99, 102–104]
4 196 exercise (1), hand
movement (1), CES (1),
nerve stimuli (1)
84.686.1 59 AD (54), 
n.r. (46)
12.286.3 small E (2), G 
(1), Mo 
(0), P (1)
Table 1. Frequency of use of 59 neuropsychological tests (cognitive domain), descriptive statistics of the populations and 
RCTs in which these tests were used, the overall Cohen’s d ES (small/medium/large) for the tests in these RCTs, and range 
of the study quality (PEDro) of RCTs (n = 63 in total) that used a given test
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Mattis Dementia Rating Scale 
(global functioning) [46, 50,
101]
3 105 pharmacological (2),
airway stimuli (1)
77.187.3 67 AD (78),
LB (22)
108.8815.7 small E (1), G 
(2), Mo 
(0), P (0)
Modified Boston Naming Test 
(language) [31, 49, 69]
3 62 pharmacological (1), 
cognitive (2)
77.487.8 76 AD (100) 10.484.6 small E (1), G 
(2), Mo 
(0), P (0)
Syndrome Kurtz Test 
(attention/memory) [52, 100]
2 290 pharmacological (2) 65.287.5 64 AD (38), 
VaD (62)
16.083.7 large E (2), G 
(0), Mo 
(0), P (0)
Digit Symbol Test (attention)
[42, 101]
2 273 pharmacological (1),
airway stimuli (1)




interference (EF) [98, 101]
2 67 pharmacological (1),
airway stimuli (1)






2 50 pharmacological (1), 
exercise stimuli (1)
71.288.1 56 AD (65), 
FTD (35)





2 38 CES (1), nerve stimuli (1) 84.486.3 59 AD (100) 9.083.8 small E (0), G 
(1), Mo 
(0), P (1)
Selective Reminding Test 
(memory) [28, 49]
2 35 cognitive (2) 72.987.1 89 AD (100) 13.3812.4 small E (2), G 
(0), Mo 
(0), P (0)
Block Design Test (EF) [84, 98] 2 31 pharmacological (2) 72.886.8 0 AD (100) 45.5814.9 small E (2), G 
(0), Mo 
(0), P (0)
The Executive Interview (EF)
[81]











1 65 pharmacological (1) 77.885.6 58 AD (66), 
VaD (11) 
– small E (0), G 
(1), Mo 
(0), P (0)
Auditory Verbal Learning 
Test – Chinese version
(memory) [33]
1 62 pharmacological (1) 83.987.6 80 AD (100) 2.681.5 small E (0), G 
(0), Mo 
(1), P (0)
Stop Signal Reaction Time 
(attention) [104]
1 61 hand movement (1) 84.785.1 58 n.r. – – E (0), G 
(0), Mo 
(1), P (0)
Attention Network Task 
(attention) [104]
1 61 hand movement (1) 84.785.1 58 n.r. – – E (0), G 
(0), Mo 
(1), P (0)
Hasegawa’s Evaluation of 
Cognitive Functioning (global 
functioning) [76]
1 60 acupuncture (1) 66.7810.5 34 VaD (100) 11.384.5 small E (0), G 
(0), Mo 
(1), P (0)
Cognitive Abilities Screening 
Instrument (global
functioning) [40]
1 60 cognitive (1) 82.385.9 67 VaD (100) 54.6815.3 small E (1), G 
(0), Mo 
(0), P (0)
Digit Cancellation Task 
(attention) [101]
1 52 airway stimuli (1) 78.287.2 69 AD (100) – – E (0), G 
(0), Mo 
(1), P (0)
Hopkins Verbal Learning 
Test – revised (memory)
[101]
1 52 airway stimuli (1) 78.287.2 69 AD (100) 3.381.5 small E (0), G 
(1), Mo 
(0), P (0)
Wisconsin Card Sorting Test
(EF) [101]
1 52 airway stimuli (1) 78.287.2 69 AD (100) – – E (0), G 
(1), Mo 
(0), P (0)
The Executive Clock Drawing 
Task 1 (EF) [110]
1 51 pharmacological (1) 77.987.0 55 AD (100) 6.283.7 small E (0), G 
(1), Mo 
(0), P (0)
The Executive Clock Drawing 
Task 2 (EF) [110]
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Figure Test – Copy (EF) [36]




Figure Test – Recall (EF) [36]










Behavioral Memory Test –
profile (memory) [36]
1 32 cognitive (1) 73.087.2 62 AD (100) 1.281.3 small E (0), G 
(1), Mo 
(0), P (0)
Attention Matrices Test 
(attention) [36]





1 16 cognitive (1) 73.884.8 82 AD (100) 13.883.6 large E (1), G 
(0), Mo 
(0), P (0)
Rapid Evaluation of Cognitive 
Functioning (global
functioning) [111]
1 31 exercise (1) 81.885.3 74 AD (100) 27.686.8 large E (0), G 
(1), Mo 
(0), P (0)
Developmental Test of Visual 
Motor Integration (perception) 
[84]





1 16 cognitive (1) 73.884.8 82 AD (100) 1.382.8 small E (1), G 
(0), Mo 
(0), P (0)
Judgment of Line Orientation 
(constructive abilities) [84]
1 16 pharmacological (1) 69.888.6 0 AD (100) 18.288.9 small E (1), G 
(0), Mo 
(0), P (0)
California Verbal Learning 
Test – delayed recall
(memory) [84]
1 16 pharmacological (1) 69.8±8.6 0 AD (100) 1.681.9 small E (1), G 
(0), Mo 
(0), P (0)
Recognition Memory Test –
faces (memory) [28]
1 16 cognitive (1) 73.884.8 82 AD (100) 28.085.9 small E (1), G 
(0), Mo 
(0), P (0)
Benton Visual Retention Test 
(memory) [49]
1 19 cognitive (1) 72.188.5 95 AD (100) 1.981.8 small E (1), G 
(0), Mo 
(0), P (0)
Recognition Memory Test – 
words (memory) [28]
1 16 cognitive (1) 73.884.8 82 AD (100) 32.788.9 small E (1), G 
(0), Mo 
(0), P (0)
Milan Overall Dementia 
Assessment (global
functioning) [59]
1 16 cognitive (1) 68.086.5 48 AD (100) – small E (0), G 
(0), Mo 
(1), P (0)
Proactive Interference Test 
(memory) [98]
1 15 pharmacological (1) 76.084.0 0 AD (100) 7.784.2 small E (1), G 
(0), Mo 
(0), P (0)
Route Test (EF) [98] 1 15 pharmacological (1) 76.084.0 0 AD (100) 15.189.6 small E (1), G 
(0), Mo 
(0), P (0)
Story Recall Test (memory) 
[98]
1 15 pharmacological (1) 76.084.0 0 AD (100) 12.0813.2 small E (1), G 
(0), Mo 
(0), P (0)
Fuld Object and Memory 
Evaluation (memory) [31]
1 13 cognitive (1) 73.386.4 69 AD (100) 24.7811.1 small E (0), G 
(1), Mo 
(0), P (0)
E = Excellent (9–10); G = good (6–8); Mo = moderate (4–5); P = poor (0–3); EF = executive functioning; CES = cranial electrostimulation; 
LB = Lewy body disease; PD = Pick’s disease; FTD = frontotemporal dementia; n.r. = not reported. a Pooled and weighted data as a function of 
the number of participants.
Table 1 (continued)
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 Study Quality 
 According to the PEDro scale, the study quality of RCTs that used neuropsychological 
tests ranged from 2 (poor) to 10 (excellent). Three RCTs with poor study quality used the 
Verbal Fluency Test Category, Digit Span Forward, Digit Span Backward, Clock Drawing 
Test, Trail Making Test-A, and Verbal Fluency Test Letters. Because these tests were also 
found in RCTs with excellent and good study quality, this had no effect on the selection pro-
cess of these neuropsychological tests.
Table 2. Reliability, validity, and summary of the psychometric properties of 10 selected neuropsychological tests (cognitive 




MMSE test-retest reliability (ICC): 0.85–0.90 [112]; 0.89 
[113]; 0.92 [114]; 0.69 [115]; 0.89 [116]; 0.80 [117]; 
0.86 [118]
inter-rater reliability: ICC = 0.69–0.78 [115]; 
κ = 0.63 [114]; ICC = 0.69 [115]
internal consistency (α): 0.54–0.96 [119]; 0.78 [120]; 
0.77 [121]; 0.68 [122]; 0.96 [123]; 0.90 [124]; 0.81 
[125]
concurrent validity with 
Wechsler adult intelligence 
scale verbal IQ (r = 0.78) 
and performance IQ 
(r = 0.66) [113]
reliable and valid test in dementia 
patients; there is a floor effect in 
severe dementia patients [119]; 
sensitivity to change over time is 
questionable because small changes 
could be due to measurement errors 
[125]
(global functioning)
ADAS-cog test-retest reliability (ICC): 0.91–0.95 [126]; 
0.65–0.92 [127]; 0.90 [128]; 0.93 [129]; 0.96 [130]; 
0.86–0.96 [131]; 0.90 [132]
inter-rater reliability: ICC = 0.65–0.95 [131]; κ = 0.99 
[130]; ICC = 0.98–0.99 [126]; ICC = 0.97–0.99 [127]; 
κ = 0.99 [133]
internal consistency (α): 0.65– 0.91 [131]; 0.87 [130]; 
0.52–0.87 [126]; 0.96 [128]; 0.15–0.93 [134]; 0.81 
[129]; 0.84 [135]
concurrent validity with 
MMSE (r = –0.63) [135]
reliable and valid test in patients 
with mild to moderate dementia(global functioning)
Verbal Fluency Test 
Category (EF)
– – no information available about 
reliability and validity for dementia 
patients
SIB (global functioning) test-retest reliability (ICC): 0.79 [136]; 0.97 [137]; 
0.87 [138]; 0.90 [139]; 0.93 [135]
inter-rater reliability: Spearman’s ρ = 0.85 [140]; 
Spearman’s ρ = 0.97 [137]; ICC = 0.99 [138]
internal consistency (α): 0.97 [136]; 0.97 [140]; 0.98 
[137]
concurrent validity with 
MMSE (r = 0.85) [140]
reliable and valid test in dementia 
patients [140]; this test is sensitive to 
changes in patients with moderate to 
severe dementia (MMSE 0–12) 
[140]; promising test for follow-up 
in therapeutic trials [138]
Digit Span Forward 
(attention)
– – no information available about 
reliability and validity for dementia 
patients; Digit Span Test as a sub-
test in the SIB was sensitive to 
change in dementia patients [141]
Verbal Fluency Test 
Letters (EF)
– – no information available about 
reliability and validity for dementia 
patients
Digit Span Backward 
(attention)
– – no information available about 
reliability and validity for dementia 
patients; Digit Span Test as a sub-
test in the SIB was sensitive to 
change in dementia patients [141]
Clock Drawing Test
(EF)
test-retest reliability (ICC): 0.70–0.78 [142]
inter-rater reliability: ICC = 0.82 [143]; ICC = 0.92 
[144]; ICC = 0.88 [145]; κ = 0.82–0.94 [146]; κ = 0.94 
[147]; κ = 0.63–1.0 [148]
internal consistency (α): 0.75 [142]
concurrent validity with 
MMSE (r = 0.13) [142]
reliable test in dementia patients
Trail Making Test-A 
(attention)
– – no information available about 




– – no information available about 
reliability and validity for dementia 
patients
EF = Executive functioning.
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 Reliability and Validity 
 Table 2 presents the reliability and validity of 10 neuropsychological tests that were used 
in  6 5 good or excellent RCTs. The global cognitive tests MMSE, ADAS-cog, and SIB were 
found to be reliable and valid tools for dementia patients. The Clock Drawing Test was reli-
able but showed an unsatisfactory concurrent validity with other tests that measured execu-
tive functioning  [149] . No reliability or validity studies with dementia patients were found 
for the Verbal Fluency Test Category, Verbal Fluency Test Letters, Trail Making Test-B, Dig-
it Span Forward, Digit Span Backward, and Trail Making Test-A.
Table 3. Frequency of use of 10 physical exercise tests (physical exercise domain), descriptive statistics of the populations 
and RCTs in which these tests were used, the overall Cohen’s d ES (small/medium/large) for the tests in these RCTs, and 



















Timed Up and Go Test 
(mobility) [45, 150, 151]




Six Minute Walk Distance 
(endurance capacity) [45, 77]
2 105 Exercise (2) 77.686.6 65 AD (39), VaD (16),
LB (16), n.r. (29)




Functional Reach Test 
(flexibility) [77, 150]




Six Meter Walk (mobility) 
[151]




Abnormal One-Leg Balance 
(balance) [151]












Five Times Sit to Stand 
(leg strength) [150]




Berg Balance Scale (balance) 
[77]
1 85 Exercise (1) 76.686.5 52 AD (61), VaD (20), 
LB (19)




30 Second Chair Stand 
(leg strength) [152]




Two Minute Step Test 
(endur-ance capacity) [152]




E = Excellent (9–10); G = good (6–8); Mo = moderate (4–5); P = poor (0–3); LB = Lewy body disease; n.r. = not reported. a Weighted data as 
a function of the number of participants.
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 Exercise Tests 
 Frequency of Test Use 
 Ten different exercise tests were used in 13 RCTs ( table 3 ). These tests measured the 
physical exercise domains endurance capacity with the Six Minute Walk Distance and Two 
Minute Step Test; muscle strength with the Five Times Sit To Stand and 30 Second Chair 
Stand; balance with the Tinetti Balance Scale, Abnormal One-Leg Balance, and Berg Balance 
Scale; mobility with the Timed Up and Go and Six Meter Walk, and flexibility with the Func-
tional Reach Test. All physical exercise tests were used in non-pharmacological RCTs, except 
for the Tinetti Balance Scale that was also used in 1 pharmacological RCT.
 Dementia Type 
 A majority of the participants were diagnosed with AD (84%) or VaD (6%). Six exercise 
tests were used only in AD patients and covered the physical exercise domains endurance 
capacity (Two Minute Step Test), muscle strength (30 Second Chair Stand), balance (Tinetti 
Balance Scale, Abnormal One-Leg Balance), and mobility (Timed Up and Go, Six Meter 
Walk). Physical exercise tests were not used in RCTs only including VaD patients. In RCTs 
that included both AD and VaD patients, 3 physical exercise tests measured the physical ex-
ercise domains endurance capacity (Six Minute Walk Distance), flexibility (Functional Reach 
Test), and balance (Berg Balance Scale).
 Study Quality 
 The study quality of RCTs ranged from 5 (moderate) to 9 (excellent). Only the Tinetti 
Balance Scale was used in a RCT with excellent study quality (PEDro 9).
 Effect Size 
 Pooled ESs of RCTs ranged from small ( d = 0.02) to large  ( d = 0.87). A large ES was found 
with the Tinetti Balance Scale  ( d = 0.87). Medium ESs were found with the Six Meter Walk 
( d = 0.58) and the Six Minute Walk Distance ( d = 0.51). 
Table 4. Recommendations of global and specific neuropsychological tests ordered on the basis of fre-
quency of test use, overall ES, study quality, reliability, and validity for global cognitive functioning, ex-
ecutive functioning, memory, and attention
Global functioning Executive functioning Memory Attention






2 MMSEa, c, d Clock Drawing Testa, c, d Eight Word Test*, c Digit Span 
Backwarda, c






4 Rapid Evaluation of
Cognitive Functioning*, b–d
Trail Making Test-Ba, c
a Frequently used in RCTs (feasibility). b Able to measure an effect (sensitivity to change). c Test was 
used in excellent/good quality RCTs (PEDro). d Reliable/valid in dementia patients.
* More research is needed to recommend these tests.
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 Reliability and Validity 
 The Timed Up and Go [intraclass correlation (ICC) = 0.985–0.988], Six Minute Walk 
Distance (ICC = 0.982–0.987), and Six Meter Walk (ICC = 0.973–0.977) showed excellent 
test-retest values for older patients with dementia  [153] . For the remaining physical exercise 
tests that are presented in  table 3 , no psychometric studies for the reliability and validity with 
dementia patients were found.
 Discussion 
 To improve the study quality and increase comparability of clinical trials and observa-
tional studies, researchers should strive to use a limited number of generally accepted, fea-
sible, reliable, and valid tests that cover the domains of cognitive and physical functioning. 
Following previous studies that recommended neuropsychological tests for the diagnoses of 
dementia  [20, 21] and studies that stated the importance of physical exercise to attenuate 
cognitive impairment in older patients with dementia  [154] , the aim of the current review 
was to give up-to-date recommendations of both neuropsychological and physical exercise 
tests for high-quality experimental research with older patients with dementia. 
 Neuropsychological Tests 
 This study revealed 59 different neuropsychological tests that were used in 63 RCTs. This 
confirms the assumption that there is a large heterogeneity in neuropsychological test use in 
RCTs with older patients with dementia. The results showed that global cognitive tests were 
used more often in comparison with neuropsychological tests that measured one specific 
cognitive domain.
 In particular, the global cognitive tests MMSE, ADAS-cog, and the SIB were standing 
out because of their excellent reliability and validity ( table 2 ), and were often used in high-
quality RCTs which suggest that they are feasible. However, for all 3 tests the sensitivity to 
change was low. In line with this, the sensitivity to change of the MMSE and ADAS-cog was 
also challenged in other studies  [140] , because changes in performance measured with these 
tests can easily be caused by small measurement errors  [125] . For the SIB, research  [140] 
showed that this test is sensitive to change in patients with severe dementia. Altogether, on 
the basis of feasibility, sensitivity, reliability, and validity we recommend the use of the SIB 
in RCTs to measure global cognitive treatment effects.
 Memory tests could not be selected in this review due to the large heterogeneity that was 
found in memory test use. Earlier work on memory tests for diagnosing dementia showed 
that verbal memory, visual memory, and non-verbal memory can be assessed with several 
tests  [20] . Most of these tests were only used once in RCTs between 2005 and 2011, and 1 test 
Table 5. Domain-specific physical exercise tests, ordered on the basis of frequency of tests use, ES, study quality, reliability, 
and validity for the physical exercise domains endurance capacity, muscle strength, balance, and mobility
Endurance capacity Muscle strength* Balance Mobility
1 Six Minute Walk Distance*, a–c Five Times Sit to Stand* Tinetti Balance Scale*, a, b Timed Up and Go*, b, c
2 30 Second Chair Stand* Six Meter Walk*, a–c
a Able to measure an effect (sensitivity to change). b Test was used in excellent/good-quality RCTs (PEDro). c Reliable/
valid in dementia patients. * More research is needed to recommend these tests.
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(Word List of the Consortium to Establish a Registry for Alzheimer’s disease) was not used 
at all in RCTs over that period. Additionally, because these tests were specifically recom-
mended for diagnosis of dementia, we suggest that it is not feasible to measure effects over 
time with these tests. Furthermore, studies that investigated the psychometric properties of 
these memory tests are lacking.
 To measure executive functioning, we recommend the use of the Verbal Fluency Test 
Category, Clock Drawing Test, Verbal Fluency Test Letters, and the Trail Making Test-B be-
cause they were frequently used in good- or excellent-quality RCTs. However, we found that 
only the Verbal Fluency Test Category was able to detect change, and only the Clock Draw-
ing Test was found to be reliable for the population of older dementia patients ( table 2 ). Since 
information and psychometric quality is in many cases still insufficient, the recommended 
selection should be used with care and further evaluation of these tests is needed. 
 For attention we recommend the Digit Span Forward, Digit Span Backward, and Trail 
Making Test-A because of their frequent use in high-quality studies. However, no studies 
were found that investigated the psychometric properties of these tests. Furthermore, the 
results showed that the sensitivity to change was small.
 Table 4 sums up the best currently available tests used in international intervention stud-
ies with older persons with dementia. Although they are widely applied, it was shown that 
the recommended neuropsychological tests lack psychometric studies. Therefore, future re-
search into the psychometric quality of the tests found in this review is essential. The recom-
mended selection of currently optimal cognitive tests should be used with care. Researchers 
are advised to select the recommended tests that most closely fit their study objectives.
 Physical Exercise Tests 
 This review found 10 different exercise tests that covered the domains endurance capac-
ity, muscle strength, balance, and mobility. However, there is a large heterogeneity in tests 
used and none of the tests were used frequently enough in RCTs to recommend them. Pre-
liminary recommendations based on the results of this review may be a first step for the se-
lection of exercise tests.
 For endurance capacity, the results showed that the Six Minute Walk Distance is reliable 
 [153] and sensitive to change. Muscle strength was measured with the Five Times Sit to Stand 
and the 30 Second Chair Stand. However, no studies were available that investigated the fea-
sibility and psychometric properties for these tests. For balance, results showed that the Ti-
netti Balance Scale was sensitive to change, but again no studies were available that investi-
gated the feasibility and psychometric properties. Mobility was measured with the Six Meter 
Walk and the Timed Up and Go. The results showed that both tests are reliable  [153] . How-
ever, only the Six Meter Walk was sensitive to change. Based on the limited information at 
hand, the best exercise tests available so far are summed up in  table 5 .
 Because of the importance of physical functioning in the disease process of dementia 
 [154] , it is essential that future research obtains more information on the feasibility, sensitiv-
ity to change, reliability, and validity of physical exercise tests that were found in this review. 
Since this information is in many cases still insufficient, the recommendation of optimal 
physical tests should be used with care.
 Conclusion 
 This review mapped the large heterogeneity in cognitive and physical functioning tests 
used in international intervention studies with older persons with dementia. The provided 
neuropsychological ( table 4 ) and exercise ( table 5 ) test recommendations from this system-
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